Preclinical characterization of AMPA receptor potentiator TAK-137 as a therapeutic drug for schizophrenia.
The downregulation of the glutamate system may be involved in positive, negative, and cognitive symptoms of schizophrenia. Through enhanced glutamate signaling, the activation of the α-amino-3-hydroxy-5-methyl-4-isoxazole-propionic acid (AMPA) receptor, an ionotropic glutamate receptor, could be a new therapeutic strategy for schizophrenia. TAK-137 is a novel AMPA receptor potentiator with minimal agonistic activity in this study, we used rodents and nonhuman primates to assess its potential as a drug for schizophrenia. At 10 mg kg